The Best Big Biotech for 2013 Motley Fool The company also anticipates phase 3 results for PEG Interferon Beta-1A in the first half of this year. Results from a phase 3 study of daclizumab HYP, another multiple sclerosis drug developed in partnership with AbbVie (NYSE: ABBV ) , are expected in ... |
